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Abstract
Background: Glioma is one of the most common and aggressive primary malignant tumor in the brain. Accumulating
evidences indicated that aberrantly expressed non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs)
and microRNAs (miRNAs), contribute to tumorigenesis. However, potential mechanisms between lncRNAs and miRNAs
in glioma remain largely unknown.
Methods: Long non-coding RNA activated by TGF-β (LncRNA-ATB) expression in glioma tissues and cells was
quantified by quantitative reverse transcription–PCR. Glioma cell lines U251 and A172 were transfected with
sh-ATB, miR-200a mimics, miR-200a inhibitors, after we assayed the cell phenotype and expression of the
relevant molecules. Dual-luciferase reporter assay, RIP and a xenograft mouse model were used to examine
the expression of sh-ATB and its target gene miR-200a.
Results: ATB is abnormally up-regulated both in glioma tissues and cell lines compared with normal brain
tissues, and glioma patients with high ATB expression had shorter overall survival time. Knockdown of ATB
significantly inhibits glioma malignancy, including cell proliferation, colony formation, migration, invasion in vitro, and
the xenograft tumor formation in vivo. In addition, ATB was confirmed to target miR-200a, and miR-200a inhibition
reversed the malignant characteristics of ATB knockdown on glioma cells. In particular, ATB may act as a
ceRNA, effectively becoming a sink for miR-200a, thereby modulating the derepression of TGF-β2.
Conclusions: Our findings suggest that ATB plays an oncogenic role of glioma cells by inhibiting miR-200a
and facilitating TGF-β2 in glioma, thereby may represent a potential therapeutic target for the treatment of
human glioma.
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Background
Glioma poses a tremendous threat to public health with
an incidence of ~5 cases per 100,000 persons and its
mortality is high around the world. Glioma is catego-
rized into four histopathologic grades (I–IV) based on
the degree of malignancy according to World Health
Organization (WHO) classification [1]. The majority pa-
tients suffered from glioma are diagnosed at the
advanced stages and exhibit extremely poor prognosis.
Combined with maximal safe surgical resection, stand-
ard radiation therapy and chemotherapy, the most ad-
vanced treatment is formed, while the most malignant
glioma called gliobastoma multiform is lined with an
average life expectancy of only 14 months [2]. Fortu-
nately, significant progress has been made in under-
standing the molecular mechanisms of glioma. Though
clinical application is largely palliative, the fatality rate
remains high in glioma patients. Therefore, it is ex-
tremely vital for us to elucidate new mechanisms associ-
ated with glioma development and establish potential
therapeutic targets for the treatment of human glioma.
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Just as the human genome project which delineated that
only a small amount of mammalian genome is encoded
proteins while the vast majority of mammalian genome
are transcribed as non-coding RNAs (ncRNAs), such as
long noncoding RNAs(lncRNAs) [3, 4]. LncRNAs are a
class of transcripts longer than 200 nucleotides in length
with little functional protein-coding ability. Recently,
many studies have demonstrated that lncRNAs could
regulate gene expression at multiple levels, including tran-
scriptional, post-transcriptional and epigenetic modulation
[5–7]. Numerous studies also indicated that dysregulated
lncRNAs are involved in the biological process during
cancer development and progression [8, 9] Examples like
lncRNAs include HOTAIR (HOX transcript antisense
intergenic RNA) [10], CRNDE(Colorectal neoplasia differ-
entially expressed) [11], MEG3 (Maternally Expressed
Gene 3) [12]. Yet, the biological roles of lncRNAs in gli-
oma are largely unknown. Long noncoding RNA activated
by TGF-β (lncRNA-ATB) was initially identified as a
lncRNA in Hepatocellular carcinoma (HCC) and its ex-
pression was significantly up-regulated both in HCC cells
and HCC samples [13]. Furthermore, ATB was also over-
expressed in other cancers, including breast cancer [14]
and colorectal cancer [15]. Therefore, the aberrant expres-
sion level of ATB was involved in a series of cancer pro-
gression. However, functional mechanism and potential
biological role of ATB in human glioma are still unknown.
MiRNAs are highly conserved among species, and play
important roles in a variety of biological and
pathological processes. A number of studies indicated
that deviant expression of miRNAs contributes to
tumorigenesis and plays a critical role in regulating the
biological behaviors of tumor cells by modulating the
protein or mRNA levels of its downstream target genes
[16, 17]. Dysregulation of miRNAs in glioma has also
been reported, and certain miRNAs have been function-
ally involved in glioma. Previous studies have demon-
strated that miR-200a as a member of the miR-200
family, which exerts as a tumor-suppressor gene and is
down-regulated in many tumors, including glioma [18].
However, the molecular mechanism of miR-200a de-
regulation and how such deregulation contributes to gli-
oma tumorigenesis remains abstruse.
In the present study, we aimed to investigate the func-
tional expression and clinical significance of ATB in hu-
man glioma. ATB was significantly up-regulated both in
glioma tissues and cell lines, whereas knockdown of
ATB diminished cell proliferation, migration and inva-
sion in glioma. In addition, the interaction among ATB,
miR-200a and TGF-β2 was also studied in order to re-
veal the underlying mechanisms. We identified that ATB
may act as a ceRNA of miR-200a, which resulted in the
derepression of TGF-β2. These findings will give a novel
strategy for the treatment of glioma.
Methods
Human tissue samples
Seventy-nine glioma tissues and 15 normal brain tissues
(NBTs) were obtained from the Department of Neurosur-
gery, the Second Affiliated Hospital of AnHui Medical
University during 2011–2014. These glioma samples were
from 50 males and 29 females with age ranging from 13 to
73 years (median, 47 years). All samples had confirmed
pathological diagnosis and were divided into low grade
(grade I–II) and high grade (grade III–IV) according to the
WHO classification by neuropathologists. Informed con-
sents were obtained from all patients, and this study was
approved by the Clinical Research Ethics Committee at the
Second Affiliated Hospital of AnHui Medical University.
Cell culture
The human glioma cell lines (U251 and A172) were pur-
chased from the Chinese Academy of Sciences (Shanghai,
China) and cultivated in Dulbecco’s modified Eagle’s
medium (DMEM; Hyclone, Logan, UT, USA) with high
glucose supplemented with 10 % fetal bovine serum (FBS,
Gibco, Carlsbad, CA, USA) and streptomycin (100 μg/ml),
penicillin (100 U/ml). All cell lines were cultured at 37 °C
in a humidified incubator with 5 % CO2.
Cell transfection
Short-hairpin RNA plasmid directed knock-down human
ATBs (GenePharma, Shanghai, China), and was indicated





AGGCG-3') and its corresponding non-targeting sequence
(sh-control) (sh-control sense: 5'-GATCCGTTCTCCGA
ACGTGTCACGTTTCAAGAGAACGTGACACGTTCG
GAGAACTTTTTTG-3' and anti-sense: 5'-AATTCA
AAAAAGTTCTCCGAACGTGTCACGTTCTCTTGA
AACGTGACACGTTCGGAGAACG-3') plasmid (Gene-
Pharma, Shanghai, China) were transfected into U251
and A172 cells respectively by using Lipofectamine2000
(Invitrogen, USA) according to the manufacturer’s proto-
col. MiR-200a mimics, miR-200a inhibitors and miR-200a
negative control (NC) were obtained from RiboBio
(RiboBio, Guangzhou, China), and transfected into cell
lines as the above described.
RNA extraction and quantitative Real-time PCR
Total RNAs were extracted from tissues and cultured cells
using Trizol reagent (Invitrogen, USA) according to the
manufacturer’s protocol. Using a Nanodrop Spectropho-
tometer (IMPLEN GmbH, Munich, Germany), RNA con-
centration and quality were determined by the 260/
280 nm absorbance. Then RNA was reversely transcribed
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into High Capacity cDNA by using PrimeScript™ RT
Master Mix (Perfect Real Time) (TaKaRa Biotechnol-
ogy, Dalian, China). Maxima SYBR Green/ROX
qPCR Master Mix (Thermo Fisher Scientific, USA)
was used for quantitative Real-time PCR. The
primers for genes were determined as follows: ATB
forward 5′-ACAAGCTGTGCAGTCTCAGG-3′, re-





miRNA First-Strand cDNA Synthesis Kit (Genecopoeia,
Guangzhou, China) was used for miRNA reverse tran-
scription and RT-QPCR was conducted using All-in-One™
miRNA qPCR Kit (Genecopoeia, Guangzhou, China) of
miR-200a and U6 (miR-200a (Cat#HmiRQP0298) and U6
(Cat#HmiRQP9001), Genecopoeia, Guangzhou, China),
respectively, by using the ABI 7100 (Applied Biosystems,
Darmstadt, Germany). GAPDH and U6 were used as in-
ternal controls for ATB, TGF-β2 and miR-200a. PCR Cyc-
ling conditions for mRNA was 2 min at 50 °C, 10 min at
95 °C and followed by 45 cycles of 95 °C for 15 s, 60 °C for
60s; for miRNA was 10 min at 95 °C and followed by
45 cycles of 95 °C for 10s, 60 °C for 20s and 72 °C for 12 s.
All qRT-PCR reactions were performed in triplicate. Rela-
tive quantification of gene expression was calculated by
the 2−ΔΔCt method.
Cell proliferation assay
Cell Counting Kit-8 (CCK8, Beyotime Institute of Bio-
technology, Jiangsu, China) was used to detect the cell,s
proliferation ability. Cells were placed into 96-well plates
at the density of 2000 cells/well. Approximately 20 μl of
CCK8 regent was added to each well after transfection,
and incubated at 37 °C for 2 h. Absorbance was mea-
sured at a wavelength of 450 nm by using a ST-360
micro-plate reader (KHB, Shanghai, China). Three repli-
cate wells were set up in each group and experiments
were repeated three times.
Clony formation assay
For the clone formation assay, approximately 200 viable
cells were seeded in 6-well plates in triplicate and incu-
bated at 37 °C with 10 % fetal bovine serum. After 12 days,
cells were fixed with 4 % polyoxymethylene and stained
with 1.5 % methylene blue. Colony formation ratio was
calculated as (number of cells/initiative cell × 100 (%)).
Wound healing assay
Cells were cultured in 6-well plates. When 95 % con-
fluency was reached, cell layers were wounded using a
10 μL tip to produce a gap, gently washed, and cultured
with serum-free medium for 24 h. The wounded gaps
were photographed with a light microscope (IX71;
Olympus, Tokyo, Japan) at × 200 magnification. Lines
were drawn along the leading edges of the cells, and the
gap distances of migrating cells from five different areas
for each wound were measured and analyzed.
Cell invasion assays
Cell invasion ability was tested by using 24-well cham-
bers with 8 μm pore size (Corning, USA). 8 × 104 cells
were resuspended in 150 μl serum-free medium and
seeded into the upper chamber pre-coated with 500 ng/ml
Matrigel solution (BD, USA) invasion assay, while
500 μl of 10 % FBS medium was placed in the lower
chamber, After incubation at 37 °C for 48 h for inva-
sion assay. Cells on the upper chamber membrane
were scraped off by cotton swab. Cells on the lower
chamber membrane were fixed with 4 % polyoxy-
methylene and stained with 0.1 % crystal violet. Five
predetermined fields were counted under a micro-
scope (×200). All assays were performed in triplicate.
Luciferase reporter assays
ATB fragment containing the predicted miR-200a bind-
ing site, the putative sequences of the binding site then
cloned into a pmirGlO Dual-luciferase miRNA Target
Expression Vector (Promega, Madison, WI, USA) to
form the reporter vector pmiRGLO-ATB-wild-type
(ATB-WT). To mutate the putative binding site of miR-
200a in ATB gene, the sequence of putative binding site
was replaced as indicated and was named as pmiRGLO-
ATB-mutated-type (ATB-MUT). pmirGLO-ATB-WT or
pmirGLO-ATB-MUT was cotransfected with miR-200a
mimics or miR-200a NC into glioma cells by using Lipo-
fectamie 2000 (Invitrogen, USA). After 48 h transfection
for luciferase assay using a Dual-Luciferase Reporter
Assay System (Promega, Madison, WI, USA) according
to the manufacturer’s protocol.
Similarly the 3’-UTR of TGF-β2 containing the puta-
tive miR-200a binding site, the putative sequences of the
binding site were cloned into a pmirGlo Dual-luciferase
miRNA Target Expression Vector to form the reporter
vector TGF-β2-wild-type (TGF-β2-WT) (GenePharma).
To mutate the putative binding site of miR-200a in the
3′-UTR-containing vector, the sequence of putative
binding site was replaced as indicated and was named as
TGF-β2-mutated-type (TGF-β2-MUT). The transfection
procedure and measurement of Luciferase activities were
handled similarly as described above. All assays were in-
dependently performed in triplicate.
RNA immunoprecipitation
EZ-Magna RIP RNA-binding protein immunoprecipita-
tion kit (Millipore, Billerica, MA, USA) was used in
RNA immunoprecipitation (RIP). RIP was implemented
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to pull down endogenous miR-200a associated with ATB
in glioma cell lines, and was performed following the
manufacturer's protocol. U251 and A172 cells were lysed
by RIP lysis buffer, 100 μL of cell lysate was incubated
with RIP immunoprecipitation buffer containing mag-
netic beads conjugated with human anti-Argonaute2
(Ago2) antibody (Millipore) and normal mouse IgG
(Millipore) was indicated as negative control. Samples
were incubated with Proteinase K buffer and then target
RNA was extracted. Purified RNA was subjected to RT-
QPCR analysis for further study.
Western blot analysis
Total proteins were extracted from the cells using RIPA
buffer with PMSF (Beyotime Institute of Biotechnology)
on ice, subjected to SDS-PAGE and electrophoretically
transferred to polyvinylidene difluoride (PVDF) mem-
branes. Membranes were incubated in 5 % nonfat milk
dissolved in Tris-buffered saline (TBS) containing 0.1 %
Tween-20 for 1.5 h at room temperature and then incu-
bated with primary antibodies as follows: TGF-β2
(1:1000, Abcam, EUGENE, USA), β-actin (1:1000, Santa
Cruz Biotechnology). After incubation with secondary
antibodies (Goat anti-rabbit or Goat anti-mouse, 1:5000
respectively; ZSGB-BIO, Beijing, China), immune com-
plexes were visualized by SuperSignal® West Femto Trial
Kit (Thermo Fisher, USA) and blot bands were scanned
using Find-do × 6 Tanon (Tanon, Shanghai, China).
Tumor xenograft formation assay in nude mice
Four-week-old female BALB/C athymic nude mice were
purchased from the National Laboratory Animal Center
(Beijing, China). Experiments with nude mice were con-
ducted strictly in accordance with a protocol approved
by the Administrative Panel on Laboratory Animal Care
of the Second Affiliated Hospital of AnHui Medical
University. The animals were free to autoclaved food
and water during the study. U251 cells transfected with
sh-control or sh-ATB were collected, and 3 × 106 cells
were subcutaneously injected into the left flank of the
nude mice. Tumor volumes were examined every 5 days,
and after 40 days, the mice were killed and tumor tissues
were excised and weighed for further study.
Immunohistochemistry
Tumor tissues from subcutaneous implantation assay were
fixed in 4 % paraformaldehyde, and then were dehydrated,
embedded in paraffin, and cut. Consecutive 4 μm thick sec-
tions were analyzed by immunohistochemistry using anti-
bodies against Ki-67 (Santa Cruz Biotechnology, USA).
Statistical analysis
Experimental data were presented as means ± standard de-
viation (SD). GraphPad Prism V5.0 (GraphPad Software,
Inc., La Jolla, CA, USA) software was used for statistical
analysis. Differences were analyzed by SPSS 17.0 statistical
software with the Student’s t-test or one-way ANOVA. The
Fig. 1 ATB was highly expressed in human glioma. a RT-QPCR analysis of ATB expression in normal brain tissues (NBTs) (n = 19), glioma
tumor tissues (n = 79) and glioma cell lines (U251 and A172). **P < 0.01 vs. NBTs group. b Expression levels of ATB in glioma tissues of
positively correlated with tumor grades. **P < 0.01 vs. NBTs group. c Kaplan-Meier analyses of the associations between ATB expression
level and overall survival of patients with human glioma (The log-rank test was used to calculate P-values). **P < 0.01 vs. low ATB expression group.
d Relative expression levels of ATB after glioma cells transfected with sh-ATB and sh-control. **P < 0.01 vs. sh-control group
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relationship between the expression of ATB, miR-200a and
TGF-β2 in tissues was analyzed with Pearson’s correlation.
Survival analysis was performed using the log-rank test in
GraphPad Prism 5. Differences were considered significant
if P < 0.05. Corresponding significance levels are indicated
in the figures.
Results
High expression of ATB was correlated with poor
outcome of glioma patients
To define the role of ATB in glioma, using real-time
quantitative PCR (RT–QPCR) analysis, we measured
ATB expression levels in 79 glioma tissues, 19 normal
brain tissues and two glioma cell lines (U251 and A172).
ATB expression levels in glioma tissues and cell lines
were significantly increased compared with normal brain
tissues (Fig. 1a). To determine whether ATB expression
was associated with the grade malignancy in gliomas, we
examine mRNA expression of ATB. We showed that
ATB expression was positively correlated with the patho-
logical grades of glioma (Fig. 1b). We then further assess
whether the expression of ATB is correlated with the
postoperative survival time of human glioma. The
Kaplan–Meier method and log-rank test revealed that
high ATB expression level was inversely correlated with
glioma patients’ overall survival (Fig. 1c).
Knockdown of ATB inhibited glioma cells proliferation,
migration, invasion in vitro
To explore the biological functions of ATB in glioma,
we firstly designed an ATB knockdown model using
transfection of sh-ATB plasmid in U251 and A172
Fig. 2 Knockdown of ATB inhibited the proliferation, migration, and invasion of glioma cells in vitro. a CCK-8 assay was performed to determine
the proliferation effect of sh-ATB and sh-control transfected U251 and A172 cells. *P < 0.05, **P < 0.01 vs. sh-control group. b Clony formation
assay was performed to detect the proliferation of U251 and A172 cells after transfected with sh-ATB and sh-control. **P < 0.01 vs. sh-control
group. c Wound healing assay to evaluate the effect of ATB on cell migration in U251 and A172 cells. **P < 0.01 < 0.05 vs. sh-control group.
d Invasion assay (use matrigel transwell chambers) for investigating cell invasiveness. **P < 0.01 vs. sh-control group. Data are presented as
mean ± SD from three independent experiments
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glioma cell lines and its knockdown efficiency was remark-
able compared with sh-control (Fig. 1d). CCK-8 assays were
performed to detect the impact of ATB knockdown on cell
viability of glioma cell lines (U251 and A172). We found
that ATB knockdown inhibited cell viability compared to
that of cells transfected with sh-control group (Fig. 2a). Fur-
thermore, colony formation assay showed that ATB knock-
down exhibited remarkable decreased clone numbers and
colony size compared with sh-control group both in U251
and A172 glioma cells (Fig. 2b). To further explore the ef-
fect of ATB on glioma cells migration and invasion. Wound
healing assay showed that knockdown of ATB impeded the
migration in monolayer cultured U251 and A172 glioma
cells (Fig. 2c). In addition, numbers of invaded cells were
obviously attenuated in the sh-ATB groups compared with
sh-control groups (Fig. 2d). Therefore, these results indi-
cated that ATB might act as an oncogene in regulating gli-
oma biological process.
ATB directly targeted miR-200a and inhibited its
expression in glioma cells
Previous studies have demonstrated that lncRNAs could
function as a competing endogenous RNAs (ceRNA) by
competitively binding miRNAs, such as miR-200a, in he-
patocellular carcinoma [8, 13, 19].
Thus we intended to investigate the potential inter-
action between ATB and miR-200a in human glioma. As
shown Fig. 3a, using QRT-PCR analysis, we found that
the expression of miR-200a was lowly expressed in gli-
oma tissues compared with normal brain tissues (NBTs).
We further found that miR-200a level in glioma tissues
was inversely correlated with pathological grades of gli-
oma (Fig. 3b). We further found that the expression level
of ATB was inversely correlated with the expression of
miR-200a in 79 human glioma patients (Fig. 3c).
Then, U251 and A172 glioma cells were transfected
with miR-200a NC, miR-200a mimics and miR-200a
inhibitors (Fig. 3d). To further elucidate whether ATB
was regulated by miR-200a, we compared ATB ex-
pression levels in U251 and A172 cells transfected
with miR-200a NC or miR-200a mimics and the re-
sults showed that overexpression of miR-200a did not
reduce the expression of ATB in glioma cells (Fig. 3e).
However, knockdown of ATB significantly increased
the expression levels of miR-200a compared to the
control group (Fig. 3f ).
Fig. 3 miR-200a expression was inversely associated with ATB expression. a MiR-200a was lowly expressed in glioma tissues and cell lines.
**P < 0.01 vs. NBTs group. b miR-200a expressed levels was inversely correlated with pathological grades of glioma. **P < 0.01 vs. NBTs
group. c Pearson’s correlation analysis of the relationship between ATB expression and miR-200a level in 79 human glioma patients. d The efficiency of
miR-200a expression levels after glioma cells transfected with miR-200a NC, miR-200a mimics and miR-200a inhibitors. **P < 0.01 vs. miR-200a NC
group. e Relative expression of ATB in U251 and A172 cells transfected with miR-200a mimics and miR-200a NC. f Relative expression of
miR-200a in U251 and A172 cells transfected with sh-ATB and sh-control. **P < 0.01 vs. sh-control group. Data were presented as mean ± SD from three
independent experiments
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To validate the direct binding between miR-200a and
ATB at endogenous levels, we constructed luciferase re-
porters, which contain wild-type (WT) or mutated
(Mut) miR-200a binding sites (Fig. 4a). We found that
overexpression of miR-200a could reduce ATB-WT
luciferase activity but not affect ATB-Mut luciferase ac-
tivity compared with miR-200a NC (Fig. 4b-c). The
microRNAs are known to bind their targets and cause
translational repression and/or RNA degradation in an
Ago2-dependent manner. To determine whether ATB
was regulated by miR-200a in such a manner, we con-
ducted anti-Ago2 RIP in U251 and A172 cells transiently
overexpressing miR-200a. Endogenous ATB pull-down
was specifically enriched in miR-200a-transfected cells
(Fig. 4d-e), supporting that miR-200 s are bona fide
ATB-targeting microRNAs. These data demonstrated
that miR-200a bound to ATB but did not induce the
degradation of ATB. All these data implied that ATB
physically correlated with the miR-200a in glioma cells.
Repression of miR-200a restored the sh-ATB induced
inhibitory effects on glioma cells
In order to investigate whether ATB exerts biological
functions through miR-200a, we perform a rescue ex-
periment. The proliferation was reduced in ATB knock-
down, while miR-200a inhibitors reversed the reduction
of proliferation and miR-200a mimics inhibited the pro-
liferation (Fig. 5a-b). Colony formation assay was used
to further assess the proliferation ability. The results
showed that ATB knockdown combined with miR-
200a overexpression resulted in significant reduction
of clone numbers and clone size of glioma cells,
whereas miR-200a inhibitors recused the clone ability
in ATB knockdown glioma cells (Fig. 5c). In addition,
ATB knockdown combined with miR-200a overex-
pression group was strongly reduced invaded cells,
and miR-200a inhibitors reversed the invasion of ATB
knockdown glioma cells (Fig. 5d). Therefore, these re-
sults suggest that ATB acts its tumor-oncogene roles
though miR-200a in glioma cells.
ATB regulated TGF-β2, a target of miR-200a, in glioma
cells
To investigate whether miR-200a targeted TGF-β2 in gli-
oma cells, and TargetScan software predicted miR-200a
binding sites in the 3’UTR of human TGF-β2 (Fig. 6a).
The expression levels of TGF-β2 in glioma cells trans-
fected with miR-200a NC, mimics and inhibitors were
tested. Overexpression of miR-200a significantly reduced
both mRNA and protein expression levels of TGF-β2
compared to miR-200a NC while inhibited miR-200a ex-
pression exhibited the opposite effects (Fig. 6b-c). The
dual-luciferase reporter assay showed that the luciferase
activity in the TGF-β2-WT was significantly decreased
after transfection with miR-200a mimics compared to
miR-200a NC, whereas the luciferase activity in the
Fig. 4 ATB directly targeted miR-200a in glioma. a The predicted miR-200a binding sites on ATB. b-c Luciferase activity in U251 and A172 glioma
cells co-transfected with miR-200a mimics and luciferase reporters containing ATB-WT or ATB-MUT transcript. **P < 0.01 vs. miR-200a NC group.
d-e RNA-IP with anti- antibody was performed in U251 and A172 cells transfected with miR-200a NC and miR-200a mimics. ATB expression level
was detected using RT-QPCR. **P < 0.01 vs. miR-200a NC group. Data were presented as mean ± SD from three independent experiments
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TGF-β2-MUT had no change in cells transfected with
miR-200a mimics and miR-200a NC group (Fig. 6d-e).
These data indicated that miR-200a inhibited TGF-β2
expressions in glioma cells by directly targeting the 3′
UTR of oncogene TGF-β2.
To explore whether ATB could function as a ceRNA
for TGF-β2 via modulating miR-200a in glioma, RT-
QPCR and Western blot assays were performed to de-
tect the mRNA and protein levels of TGF-β2 after cells
transfected with sh-ATB combined with miR-200a
mimics, miR-200a inhibitors. Knockdown of ATB re-
duced the expression of TGF-β2 at mRNA and protein
levels, and sh-ATB combined with miR-200a mimics sig-
nificantly reduced the expression levels of TGF-β2, in
contrast, miR-200a inhibitors restored the reduction of
TGF-β2 expression in ATB knockdown glioma cells
(Fig. 7a-c). Additionally, we further found that the ex-
pression levels of TGF-β2 was inversely correlated with
the expression of miR-200a and positively associated
with ATB in 79 human glioma patients (Fig. 7d-e). These
findings suggest that ATB functions as a ceRNA to regu-
late the expression of TGF-β2 by releasing miR-200a in
glioma cells.
ATB inhibition significantly suppressed tumor growth in
vivo
To evaluate the functional roles of ATB in vivo, sh-
control/sh-ATB transfected U251 cells were inoculated
Fig. 5 Repression of miR-200a abolished the sh-ATB induced inhibitory effects on glioma cells. a-b CCK-8 assay was performed to determine the
proliferation after co-transfected with sh-ATB and miR-200a mimics or miR-200a inhibitors. *P < 0.05, **P < 0.01 vs. sh-control group; #P < 0.05 vs.
sh-ATB group. c Colony formation assay was performed to detect the proliferation effect of U251 and A172 cells after co-transfected with sh-ATB
and miR-200a mimics or miR-200a inhibitors. *P < 0.05, **P < 0.01 vs. sh-control group; #P < 0.05, ##P < 0.01 vs. sh-ATB group. d Invasion assay (use
matrigel transwell chambers) in U251 and A172 cells was performed to determined cell invasiveness after co-transfected with sh-ATB and
miR-200a mimics or miR-200a inhibitors. **P < 0.01 vs. sh-control group; #P < 0.05, ##P < 0.01 vs. sh-ATB group. Data are presented as mean ± SD from
three independent experiments
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into nude mice respectively. Tumor volumes in the
sh-ATB group were obviously smaller compared with
the sh-control group (Fig. 8a-b). Also, tumor weights in
the sh-ATB group were significantly lower than in the sh-
control group (Fig. 8c). Ki-67 staining was performed to
measure the proliferation ability in xenografted tumor tis-
sues. As shown in Fig. 8d, the sh-ATB group had fewer
proliferative cells than that in the sh-control group.
Discussion
Nowadays, operation and chemoradiotherapy termed as
comprehensive treatments are the main means for the
treatment of glioma patients, although it can alleviate
patients’,suffering and prolong life-span, the prognosis is
still poor [20, 21]. Therefore, it is urgent for us to find
new effective therapies for glioma patients. Recent stud-
ies have suggested that dysregulation of lncRNAs are in-
volved in the tumorigenesis and progression of multiple
cancers, including glioma [22, 23]. Consequently, under-
standing the underlying mechanisms and biological
functions of lncRNAs in glioma may give us a new direc-
tion for the treatment of glioma patients.
A number of studies have demonstrated that lncRNAs
play considerable functional roles in human malignant
Fig. 6 miR-200a directly targeted the 3′UTR of oncogene TGF-β2 and inhibits its expression in glioma cells. a The predicted of miR-200a binding
sites in the 3′-UTR region of TGF-β2 (TGF-β2-3′-UTR-WT) and the corresponding mutant sequence (TGF-β2-3′UTR-MUT) was shown. b-c Relative
expression of TGF-β2 mRNA and protein levels in U251 and A172 cells after transfected with miR-200a mimics, miR-200a inhibitors, and miR-200a
NC. *P < 0.05, **P < 0.01 vs. miR-200a NC group. d-e Luciferase activity in U251 and A172 cells co-transfected with miR-200a mimics and luciferase
reporters containing TGF-β2 wild type (WT) or mutant type (MUT) 3′-UTR. **P < 0.01 vs. miR-200a NC group. Data are presented as mean ± SD
from three independent experiments
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tumor [24–27]. Long non-coding RNA ATB was overex-
pressed in hepatocellular carcinoma, which promotes
HCC cells invasion and tumor growth [13]. Further-
more, ATB is also found as a novel biomarker of
lncRNA, indicative of a poor prognosis in gastric cancer
and colon cancer patients [15, 28]. In the present study,
our results confirmed that ATB was highly expressed in
glioma, and high ATB expression was associated with a
poor clinical outcome in glioma patients. Knockdown of
ATB suppressed the proliferation, migration and inva-
sion of glioma cells. In addition, the in vivo experiments
also supported the above findings, suggesting that ATB
exerted as an oncogene in human glioma. Moreover,
overexpression of ATB in breast cancer cells promotes
the invasiveness, which is consistent with the results of
our study [14].
MiRNAs may function as oncogenes and/or tumor
suppressors in many cellular processes during cancer
initiation and progression [29]. Accumulating evidences
have showed that lncRNAs can antagonize miRNA func-
tion by competing with miRNAs for binding to shared
target mRNAs, and then to silence target mRNAs [30].
Long noncoding RNA ANRIL promotes tumor growth
by epigenetically repressing of miR-99a/miR-449a in hu-
man gastric cancer [31]. Gas5 suppresses the malignant
biological characteristics by down-regulating miR-222 in
human glioma [32]. Growing number of present work
confirmed the common existence of a widespread
Fig. 7 ATB as a ceRNA for TGF-β2 by releasing miR-200a in glioma cells. a-b RT-QPCR and c Western blot assays were performed to detect the
mRNA and protein levels of TGF-β2 after cells transfected with sh-ATB and miR-200a mimics or miR-200a inhibitors. **P < 0.01 vs. sh-control group;
#P < 0.05, ##P < 0.01 vs. sh-ATB group. Data are presented as mean ± SD from three independent experiments. d Pearson’s correlation analysis of
the relationship between TGF-β2 expression and miR-200a expression. e Pearson’s correlation analysis of the relationship between TGF-β2
expression and ATB expression
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interaction network of competitive endogenous RNAs
(ceRNAs), in which lncRNAs may exert functions
through targeting miRNAs and regulating their function
role [19, 33]. ATB could promote the invasion-
metastasis cascade in HCC by negative regulating of
miR-200 family [13]. Previous study showed that down-
regulation of miR-200a promoted glioma malignancy by
up-regulating SIM2-s [18]. Our present study confirmed
that miR-200a was significantly decreased in glioma tis-
sues and inversely correlated with ATB. To explore
whether ATB has miR-200a binding site in glioma cells,
and was confirmed by luciferase reporter assays and RIP.
We verified that ATB is directly bound to miR-200a on
ATB transcript. RNA-IP assay showed that the expres-
sion of ATB immunoprecipitated with in the miR-200a
overexpression group was significantly increased. Mean-
while, we found that ATB exerted the function of anti-
tumor by miR-200a in glioma cells. Taken all together,
these data strongly suggested that ATB directly targets
miR-200a and affects the biological characteristic of gli-
oma cells by negatively regulating miR-200a.
The transforming growth factor-β2 (TGF-β2) belongs to
TGF-β family, functioned as an oncogene in several cancer
types, which promote cancer cells, malignant behaviors
[34]. Recent study has reported that miR-200a suppresses
renal cell carcinoma development by directly targeting
TGF-β2 [35] and miR-200a prevents renal fibrogenesis by
suppressing of TGF-β2 [36]. Consistent with previous
studies, we confirmed that miR-200a regulated the ex-
pression of TGF-β2 via targeting the 3′UTR of TGF-β2.
Emerging evidences indicated that lncRNAs play a
critical role in a variety of cellar biological processes by
acting as a ceRNA or a molecular sponge in modulating
the role and functions of miRNAs [30, 37]. These
lncRNAs act as a natural miRNA sponge to control en-
dogenous miRNAs by using shared miRNAs responsive
elements (MREs) and then modulating the derepression
of these miRNAs targets via post-transcriptional regula-
tion [38]. For instance, HOTAIR, a well-known lncRNA
could inhibit the expression of FGF1 by regulating miR-
326 in human glioma [39], and also functioned as a
competing endogenous RNA to regulate HER2 expres-
sion by sponging miR-331-3p in promoting gastric can-
cer [40]. To further explore whether TGF-β2 is involved
in the ATB acts as a ceRNA in regulating the biological
characteristics of glioma by modulating miR-200a. We
demonstrated that miR-200a reversed the reduction of
TGF-β2 mediated by ATB knockdown. In addition, we
found that TGF-β2 expression was negatively correlated
with miR-200a, but positively associated with ATB in
glioma tissues. These results suggested that ATB func-
tions as a ceRNA via decreasing miR-200a, up-regulating
TGF-β2 in human glioma.
Conclusion
In summary, we first reported that ATB was highly
expressed in glioma tissues and acted as an oncogene,
which serves a key function in regulating glioma
malignancy. ATB knockdown suppressed glioma bio-
logical characteristics by directly targeting miR-200a and
Fig. 8 Knockdown of ATB inhibited U251 cell growth in vivo. a sh-control or sh-ATB was transfected into U251 cells, which were injected in nude
mice, respectively. b Tumor volumes were calculated every 5 days after injection. Bars indicate SD. c Tumor weights are represented as means of
tumor weights ± SD. d Immunohistochemical (IHC) staining expression of Ki-67 in subcutaneous tumors of mice injected with sh-control or sh-ATB
cells. Data are presented as mean ± s.d. from three independent experiments. **P < 0.01 vs. sh-control group
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negatively regulating its expression in glioma cells.
TGF-β2, a target oncogene, is directly bound to
tumor-suppressor gene miR-200a and is involved in
ATB function as a ceRNA for miR-200a in glioma.
Therefore, understanding the functional role of ATB
in glioma will provide us a novel strategy to find po-
tential therapeutic targets for the treatment of glioma.
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